Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Significant Accounting Policies (Narrative) (Details)

v3.10.0.1
Basis of Presentation and Significant Accounting Policies (Narrative) (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Jan. 19, 2018
Oct. 31, 2017
May 31, 2017
Jun. 30, 2016
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Noncontrolling Interest [Line Items]                      
Accumulated deficit         $ 79,642,034       $ 79,642,034   $ 68,846,326
Net loss         3,923,586     $ 2,504,178 11,463,927 $ 9,053,987  
Cash and cash equivalents         20,962,319       20,962,319   9,763,067
Revenue         1,840,009     470,823 3,735,713 906,313  
Non-controlling interest         265,024     203,371 668,219 344,328  
Reimbursable funds                 15,200,000    
Unearned revenue liability balance                 5,200,000    
Removal of changes in restricted cash from Consolidated Statements of Cash Flows due to adoption of ASU 2016-18                 2,292 98,879  
Reverse stock split When the reverse stock split became effective, every 10 shares of the Company’s issued and outstanding common stock were combined into one share of common stock. Effecting the reverse stock split reduced the number of issued and outstanding common stock from approximately 42 million shares to approximately 4.2 million.                    
Proceeds from financings                 18,800,000    
Proceeds from exercise of warrants                 $ 4,838,593  
Number of warrant exercised                 3,054,667  
Proceeds from deferred revenue                 $ 3,100,000    
Grant received for preclinical activities from CPRIT                 200,000    
Deferred revenue, net of current portion         200,000       200,000   $ 200,000
Understatement of income tax benefit due to immaterial error correction           $ 235,000 $ 205,000        
Income tax benefit         225,389 $ 235,000 $ 205,000 665,080  
Grant Revenue [Member]                      
Noncontrolling Interest [Line Items]                      
Revenue         $ 1,800,000     $ 500,000 3,700,000 $ 900,000  
Heat Biologics I, Inc. [Member]                      
Noncontrolling Interest [Line Items]                      
Ownership interest in subsidiary                     92.50%
Non-controlling interest                 $ 223,487    
Pelican Therapeutics, Inc. [Member]                      
Noncontrolling Interest [Line Items]                      
Percentage of voting interests acquired in acquisition         80.00%     80.00% 80.00% 80.00%  
Revenue                 $ 15,200,000    
Non-controlling interest                 444,732    
Contract value                 7,600,000    
Pelican Therapeutics, Inc. [Member] | Grant Revenue [Member]                      
Noncontrolling Interest [Line Items]                      
Revenue       $ 15,200,000         $ 3,700,000    
Pelican Therapeutics, Inc. [Member] | Second tranche [Member] | Grant Revenue [Member]                      
Noncontrolling Interest [Line Items]                      
Revenue   $ 6,500,000                  
Pelican Therapeutics, Inc. [Member] | First tranche [Member] | Grant Revenue [Member]                      
Noncontrolling Interest [Line Items]                      
Revenue     $ 1,800,000